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tered insulin responsiveness in IGT men compared with 
NGT men, while there were no differences in basal gene ex-
pression.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Type 2 diabetes mellitus (T2DM) is one of the major 
causes of morbidity and mortality in the world and its 
prevalence has been rapidly increasing with currently 
about 200 million patients worldwide  [1] . The impaired 
glucose tolerance (IGT) state represents an intermediate 
phase between the normal glucose tolerance (NGT) state 
and T2DM  [2] . Insulin resistance and   -cell dysfunction 
occur very early on in the disease progress  [3] . Insulin-re-
sistant skeletal muscle is characterized by a reduced ability 
to oxidize lipids  [4] , an impaired switch between fat and 
carbohydrate oxidation in the postprandial state (metabol-
ic inflexibility)  [4, 5] despite elevated lipids in the circula-
tion (‘lipid overflow’), and an accumulation of triglycer-
ides within skeletal muscle  [5, 6] . This may lead to the ac-
cumulation of lipid intermediates, such as diacylglycerols, 
ceramides, and long-chain fatty acyl-CoA, that can be 
linked to defects in the insulin signaling cascade  [7–9] .
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 Abstract 
 Background:  The impaired glucose tolerance (IGT) state is 
characterized by insulin resistance. Disturbances in fatty 
acid (FA) metabolism may underlie this reduced insulin sen-
sitivity. The aim of this study was to investigate whether the 
prediabetic state is accompanied by changes in the expres-
sion of genes involved in FA handling during fasting and in 
insulin-mediated conditions and to study the impact of 
weight loss.  Methods:  Seven IGT men and 5 men with nor-
mal glucose tolerance (NGT), comparable in terms of age 
and BMI, participated in the study. The 5 IGT men followed 
a 12-week weight loss program. Muscle biopsies were taken 
and the expression of 6 genes was investigated.  Results: 
 Subjects had a reduction of 15.5  8 4.3 kg in body weight. 
Baseline gene expression was not different between NGT 
and IGT men. After a hyperinsulinemic clamp, there was an 
overall upregulation of PGC1  , SREBP-1c, SREBP-2, and ACC-
2. The upregulation of SREBP-2 was more pronounced in 
IGT men (p = 0.049). Weight loss significantly increased in-
sulin sensitivity by 71%, which was not reflected in altered 
gene expression profiles.  Conclusions:  SREBP-2 shows al-
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 The metabolic and molecular mechanisms responsible 
for the reduced fat oxidation are not completely under-
stood  [10] . It has been suggested that enzymes involved in 
fatty acid (FA) transport and metabolism are altered and 
that the metabolic profile of the insulin-resistant muscle 
is oriented more towards fat storage than towards oxida-
tion  [11, 12] . Acetyl-CoA carboxylase (ACC)-2 may play 
an important role in this diminished lipid oxidation  [13] . 
It has been shown that T2DM subjects have a significant-
ly elevated ACC-2 expression in skeletal muscle  [14] . 
Meanwhile, ACC-2 mRNA expression is significantly re-
duced as a result of lifestyle intervention in IGT subjects 
 [15] together with improvements in fat oxidation. Anoth-
er potential mechanism controlling intramyocellular tri-
glyceride content is the lipogenic pathway in muscle. 
SREBPs are central regulators of lipid biosynthesis  [16] . It 
has been shown that SREBP-1c expression is significantly 
reduced in the skeletal muscle of T2DM patients  [17] . 
SREBP-2 mainly activates genes involved in cholesterol 
synthesis in the liver  [18] . The exact role of SREBP-2 in 
skeletal muscle metabolism remains to be elucidated. 
Furthermore, an impaired mitochondrial function or re-
duced content have been proposed as underlying defects 
in fat oxidation and insulin resistance  [19, 20] , though 
several recent studies shed doubt on this concept  [21, 22] . 
A set of genes involved in oxidative phosphorylation, in-
cluding peroxisomal proliferator activator receptor   co-
activator 1  (PGC1  ), has recently been found to be co-
ordinately downregulated in the skeletal muscle of T2DM 
patients  [23, 24] . Finally, several studies have also indi-
cated important defects in the capability of insulin to
regulate gene expression in peripheral tissues in T2DM 
 [25, 26] . The insulin-induced regulation of PGC1  and 
SREBP-1c mRNA expression has been shown to be im-
paired in the skeletal muscle of T2DM patients  [14, 25] .
 There are indications that weight loss is able to partly 
improve the switch between fat and carbohydrate oxida-
tion in the postprandial state in obese or IGT subjects  [5, 
27] , which may be related to the effect of insulin on genes 
involved in lipid metabolism. Surgically-induced weight 
loss increased PGC1  (mRNA expression) in previous 
morbidly obese subjects  [28, 29] , while Berggren et al.  [30] 
observed no change in PGC1  expression after weight 
loss in obese subjects.
 The current study was undertaken to compare the ex-
pression levels of candidate genes involved in lipid metab-
olism in muscle biopsies of obese NGT and IGT subjects 
during fasting or in insulin-mediated conditions. More-
over, the impact of weight loss on FA metabolism-related 
gene expression was also studied in the obese IGT subjects.
 Research Design and Methods 
 Subjects 
 Five obese NGT men and 7 obese IGT men, comparable in 
terms of age and Body Mass Index (BMI), participated in the 
study. Glucose tolerance was measured using a standard oral glu-
cose tolerance test with capillary plasma sampling at baseline and 
after 2 h according to World Health Organization (WHO) guide-
lines. Additional inclusion criteria were: obesity (BMI  1 30), dia-
stolic blood pressure  ! 100 mm Hg, no major organ dysfunction, 
and no use of lipid- or glucose-lowering medication. The NGT 
men had no family history of diabetes. The subjects were not in-
volved in any organized sports activities for more than 3 h a week. 
The experimental protocol was approved by the local Medical 
Ethical Committee of Maastricht University. All subjects were in-
formed about the aims of the study and gave their written in-
formed consent.
 Study Design 
 The NGT men and the IGT men underwent measurements for 
body composition, aerobic capacity, and insulin sensitivity. Body 
weight (BW) was determined using an electronic scale. Body 
composition [fat mass (FM) and fat-free mass (FFM)] was deter-
mined by hydrostatic weighing with simultaneous correction for 
lung volume, and the body fat percentage was calculated accord-
ing to the equation of Siri  [31] . Waist and hip circumferences were 
measured to the nearest 1 cm. Peak oxygen uptake (V O 2 max) was 
determined during an incremental exhaustive bicycle ergometer 
test. Insulin sensitivity was determined with a hyperinsulinemic 
euglycemic clamp as described below. Percutaneous needle biop-
sies were taken, at the beginning and at the end of the hyperinsu-
linemic clamp, from the vastus lateralis muscle under local anes-
thesia of the skin using the Bergström method with suction ( fig. 1 ) 
 [32] . The biopsies were immediately frozen in liquid nitrogen. 
From 5 men in the IGT group, we obtained complete data on skel-
etal muscle gene expression before and after a 12-week weight loss 
program ( fig. 1 ). During the first 4 weeks, the subjects were pro-
vided with a very low-calorie diet (2 MJ/day) based on shakes 
(Modifast Nutrition & Santé, Breda, The Netherlands) containing 
all of the essential macro- and micronutrients. From weeks 5–8, 
the shakes were gradually replaced by normal meals, increasing 
the energy content of the diet up to 4.2 MJ/day. In the last 4 weeks, 
the subjects were kept in energy balance by prescribing detailed 
weekly menus. After at least 2 weeks of energy balance, the mea-
surements described above were repeated (weeks 10–12).
 Euglycemic-Hyperinsulinemic Clamp 
 Subjects arrived at the laboratory by car or public transport 
after an overnight fast (10–12 h). Insulin was infused at a constant 
rate (1 mU  kg BW –1  min –1 ) with glucose clamped at 4.5  8 0.2 
mmol/l with an intravenous infusion of 20% w/v glucose solution. 
Insulin sensitivity (M value) was calculated as the glucose infu-
sion rate per kg of FFM (  mol  kg FFM –1  min –1 ) during a steady 
state of 30 min after at least 120 min of insulin infusion.
 Biochemical Analysis 
 The muscle biopsies were homogenized in ice-cold Tris-EDTA 
buffer at a pH of 7.4. The homogenates were subsequently soni-
cated for 4  ! 15 s and were centrifuged at 10,000  g for 2 min at 
4   °   C to remove cell debris. Citrate synthase (CS) was determined 
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using the method of Sherpherd and Garland  [33] , whereas 3-hy-
droxyacyl-CoA dehydrogenase (HAD) was assayed according to 
Bergmeyer  [34] .
 Total RNA Preparation 
 Total RNA was extracted from frozen skeletal muscle speci-
mens using TRIzol reagent (Invitrogen, Breda, The Netherlands) 
and purified using an RNeasy Mini Kit (Qiagen, Venlo, The Neth-
erlands). RNA quantity was measured using an ND-100 spectro-
photometer (Isogen Life Science, Ijsselstein, The Netherlands), 
and RNA integrity was analyzed on an Agilent 2100 Bioanalyzer 
(Agilent Technologies, Amsterdam, The Netherlands) using 
nanochips according to manufacturer’s instructions. An RNA
Integrity Number above 6 was judged acceptable for this study.
 Quantification of Messenger RNAs 
 Real-time quantitative polymerase chain reaction (PCR) was 
used to analyze RNA samples. Total RNA was reverse-transcribed 
in a 20-  l reaction using an iScript cDNA Synthesis Kit (Bio-Rad, 
Veenendaal, The Netherlands) according to the manufacturer’s 
instructions. Primers were designed using Beacon Designer or 
were obtained from Primer Bank ( table  1 ). Real-time PCR was 
carried out in an iCycler thermal cycler upgraded with an MyiQ TM 
single-color real-time PCR detection system (Bio-Rad). Gene ex-
Oral Glucose Tolerance Test (OGTT)
5 NGT 7 IGT
Obese men (BMI >30)
Body weight
Body composition (hydrostatic weighing)
Waist/hip ratio
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 Fig. 1. Scheme of the study design. 
Table 1.  Sequences of the primers used for mRNA quantitation by RT-PCR
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pression levels were normalized using housekeeping genes Glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) and Ribosom-
al Protein L13a (RPL13a). GeNorm was used to test the stability 
of the housekeeping genes  [35] .
 Statistical Analysis 
 Using our sample size of 5 NGT subjects and 7 IGT subjects, 
our study had enough power (  = 0.8 and   = 0.05) to detect an 
effect size of 1.82 as normalized expression between the NGT and 
IGT groups for all genes. Using our sample size of 5 IGT subjects, 
our study had enough power (  = 0.8 and   = 0.05) to detect an 
effect size of 1.68 as normalized expression in IGT subjects before 
weight loss compared to the same subjects after weight loss for all 
genes. Power calculations were performed using G * Power 1.3 (In-
stitute for Experimental Psychology, Heinrich Heine University, 
Düsseldorf, Germany). Differences between NGT (n = 5) and IGT 
men (n = 7) were statistically examined using a 2-tailed Student’s 
t test for unpaired samples or they were analyzed over time by 
ANOVA (repeated measures). IGT men before (n = 5) and after 
weight loss (n = 5) were compared using a 2-tailed Student’s t test 
for paired samples. Results are given as means  8 SEM. p  ! 0.05 
was considered statistically significant. The statistical analysis 
was performed using SPSS 16.0 for Macintosh.
 Results 
 Subject Characteristics 
 The IGT and NGT men were comparable in terms of 
age and BMI. They were also comparable with respect to 
body composition and peak oxygen uptake ( table 2 ). The 
IGT men tended to be more insulin resistant than the 

























































































































Before clamp After clamp
 Fig. 2. The effect of insulin on skeletal 
muscle gene expression. The mRNA levels 
of the various genes were determined by 
quantitative real-time PCR in skeletal 
muscle biopsies of the NGT (n = 5) and 
IGT (n = 7) subjects before and after
a 2-hour euglycemic-hyperinsulinemic 
clamp. Results are presented as means  8 
SEM. 
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ing glucose concentrations (not significant), and had, by 
definition, increased 2-hour glucose concentrations.
 The dietary intervention induced a reduction of 15.5 
 8 4.3 kg in body weight, 20% of which could be attrib-
uted to a loss of FFM and 80% of which could be attrib-
uted to a loss of FM ( table 2 ). After weight loss, there was 
a significant increase in insulin sensitivity (p = 0.02) ( ta-
ble 3 ). Skeletal muscle CS activity (p = 0.08) tended to in-
crease after weight loss, while HAD activity did not 
change ( table 2 ). The peak oxygen uptake did not change 
after weight loss ( table 2 ).
 Fasting glucose, insulin, and free FA were not signifi-
cantly different between IGT and NGT men. After weight 
loss, IGT men had a significantly lower insulin concen-
tration during fasting (p = 0.03) and during the steady 
state at the end of the clamp (p = 0.04). Furthermore, the 
free FA concentration tended to be lower in the IGT men 
after weight loss in the steady state period at the end of 
the clamp compared to before weight loss (p = 0.07) ( ta-
ble 3 ).
Table 2.  Clinical characteristics of study subjects
NGT (n = 5) IGT (n = 7) p value I GT (n = 5) p value
before WL after WL
Age, years 59.881.9 57.183.5 0.57
Body weight, kg 99.886.5 92.983.4 0.33 95.584.0 80.083.7 0.001
BMI 33.881.7 32.280.7 0.34 32.380.6 27.080.8 0.001
Body fat, % 35.982.2 32.581.3 0.18 34.081.1 25.081.8 0.002
FFM, kg 63.683.3 62.681.3 0.75 62.981.7 59.781.9 0.04
FM, kg 36.284.2 30.582.2 0.23 32.682.3 20.282.1 0.001
Waist/hip ratio 1.0280.03 1.0380.01 0.62 1.0580.01 0.9880.01 0.01
VO2max (ml O2kg FFM–1min–1) 40.382.7 39.581.8 0.82 41.482.2 42.683.8 0.96
FPG, mmol/l 5.880.3 6.680.3 0.12
2hPG, mmol/l 7.580.5 11.780.7 0.001
CS, U/g wet weight 3.080.8 4.280.4 0.20 4.380.5 7.481.2 0.08
HAD, U/g wet weight 4.581.0 5.080.5 0.66 5.080.8 3.781.0 0.43
Val ues are means 8 SEM. NGT and IGT were compared using a 2-tailed Student’s t test for unpaired samples. IGT before weight 
loss and IGT after weight loss were compared using a Student’s t test for paired samples. WL = Weight loss; FPG = fasting plasma glu-
cose; 2hPG = 2-hour plasma glucose; HAD = 3-hydroxyacyl-CoA dehydrogenase; CS = citrase synthase.
Table 3.  M value and plasma metabolites during fasting and during the steady state of the euglycemic hyperinsulinemic clamp
NGT (n = 5) IGT (n = 7) IGT
fasting SS fasting SS before WL (n = 5) a fter WL (n = 5)
fasting SS fa sting SS
Glucose, mmol/l 5.980.1 4.580.1 6.280.2 4.480.1 6.280.3 4.580.1 5.480.2 4.580.1
Insulin, mU/l 12.382.3 106.886.9 15.582.8 94.587.2 14.282.0 99.289.5 8.680.6* 69.681.4*
Free FA, mol/l 6298120 162828 6528139 149819 6528278 141845 562859 72814#
Insulin sensitivity1 n.a. 34.286.7 n.a. 20.884.1# n.a. 21.785.0 n.a. 37.185.7*
Val ues are means 8 SEM. NGT and IGT were compared using a 2-tailed Student’s t test for unpaired samples, # p < 0.10. IGT be-
fore weight loss and IGT after weight loss were compared using a Student’s t test for paired samples, * p < 0.05 and # p < 0.10.  WL = 
Weight loss; SS = steady state at the end of the clamp. 1 M value calculated as molkg FFM–1min–1.
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 Skeletal Muscle Gene Expression during Fasting and 
during a Euglycemic Hyperinsulinemic Clamp 
 To determine fasting gene expression and the effect of 
insulin on skeletal muscle gene expression, 6 genes in-
volved in FA partitioning and oxidation were investigat-
ed. Fasting gene expression was not significantly dif-
ferent between the NGT and IGT men for all the genes 
tested. After the hyperinsulinemic clamp there was an 
overall upregulation of PGC1  (p = 0.003), SREBP-1c
(p = 0.005), SREBP-2 (p = 0.005), and ACC-2 (p = 0.03) 
( fig. 2 a, c, d, f). For SREBP-2, the upregulation was more 
pronounced in IGT versus NGT men (  0.23  8 0.15 vs. 
  0.07  8 0.18, respectively; p = 0.049) ( fig.  2 d,  3 ). The 
2-hour insulin infusion did not affect PPAR  and 
ChREBP expression ( fig. 2 b, e).
 The Effect of Weight Loss on Skeletal Muscle Gene 
Expression 
 We investigated whether weight loss could induce 
changes in the mRNA level of the 6 target genes in IGT 
men. Although the IGT men had an improved insulin 
sensitivity after weight loss (p = 0.02), this effect could not 
be detected on a transcriptional level ( fig. 4 ). Both PGC1  
and PPAR  , genes thought to be involved in skeletal mus-
cle fat oxidation, showed no increase in expression after 
weight loss ( fig. 4 a, b). There was also no effect of weight 
loss on the expression of SREBP-1c, SREBP-2, ChREBP, 
or ACC-2 ( fig. 4 c–f).
SREBP-2













































































































































 Fig. 4. Skeletal muscle gene expression in 
IGT men before and after weight loss. The 
mRNA levels of the various genes were de-
termined by quantitative real-time PCR in 
skeletal muscle biopsies of IGT (n = 5) sub-
jects before and after weight loss. A two-
tailed paired Student’s t test was used. 
 Fig. 3. Change in SREBP-2 expression in 
NGT vs. IGT men induced by a 2-hour eu-
glycemic-hyperinsulinemic clamp.  *   p  ! 
0.05 represents a significant difference be-
tween NGT and IGT men. Data are pre-
sented as values after the clamp minus val-
ues before the clamp. 
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 Discussion 
 In the present study, we have demonstrated that 
SREBP-2 may play an important role in skeletal muscle 
FA handling since it was differentially expressed between 
NGT and IGT men after insulin infusion. The basal level 
of SREBP-2 in the IGT subjects was lower than in the 
NGT subjects, though not significantly different. The in-
fusion of insulin in the IGT men acutely upregulated 
SREBP-2 expression to levels comparable in the NGT 
subjects. The lower baseline expression could have con-
tributed to the more pronounced increase of SREBP-2 ex-
pression in IGT men compared with NGT men. SREBP-2 
is a member of the SREBP family, a group of membrane-
bound transcription factors which are synthesized as in-
active precursor proteins. They undergo posttranslation-
al cleavage in order to enter the nucleus and stimulate the 
transcription of numerous target genes  [36] . In liver, 
SREBP-2 mainly activates genes involved in cholesterol 
synthesis  [18] . The exact role of SREBP-2 in skeletal mus-
cle metabolism remains to be elucidated. Recent studies 
have demonstrated that SREBPs are central regulators of 
membrane lipid biosynthesis  [16, 37] . Mahoney et al.  [38] 
reported an upregulation of SREBP-2 in skeletal muscle 
after eccentric exercise. They suggested that SREBP-2 
may activate a transcriptional program for de novo mem-
brane synthesis since eccentric exercise can induce mem-
brane damage. Based on these findings, it can be specu-
lated that in our study SREBP-2 is more upregulated in 
IGT men after insulin infusion to repair the mitochon-
drial membrane damage possibly induced by lipid per-
oxidation. However, the present study has no data to ad-
dress this hypothesis. It is known from the literature that 
IGT men suffer from oxidative stress, deﬁned as a persis-
tent imbalance between the production of highly reactive 
oxygen/nitrogen species  [39] . Mitochondria are a major 
source of reactive oxygen species. The accumulation of 
FA in the vicinity of the mitochondrial matrix makes 
them prone to lipid peroxidation, which may eventually 
result in damaged mitochondrial proteins and a reduced 
oxidative capacity  [40, 41] . SREBP-2 showed altered insu-
lin responsiveness in IGT men compared with NGT men 
and may thus be an interesting candidate for further re-
search to elucidate its exact role in skeletal muscle.
 Besides SREBP-2, several other genes were upregulat-
ed after the euglycemic-hyperinsulinemic clamp, includ-
ing PGC1  , SREBP-1c, and ACC-2. Our data are consis-
tent with the results of Ling et al.  [42] who found that 
insulin increased the mRNA level of PGC1  in muscle 
biopsies from healthy young and elderly twins before and 
after a clamp. This increase can mediate the expression 
of GLUT-4 in large part by binding to and coactivating 
the muscle-selective transcription factor myocyte-specif-
ic enhancer factor 2C (MEF2C)  [43, 44] . Many groups 
have established that insulin upregulates SREBP-1c 
mRNA and mature SREBP-1 protein and is accompanied 
by increases in FA biosynthetic gene expression  [17, 25] . 
ACC-2 is one of the genes that catalyze the synthesis of 
malonyl-CoA from acetyl-CoA. Increased levels of mal-
onyl-CoA lead to the inhibition of CPT-1 and, subse-
quently, to the inhibition of mitochondrial FA oxidation 
 [45, 46] . Indeed, our results show an upregulation of 
SREBP-1c and, subsequently, an upregulation of ACC-2 
after insulin stimulation.
 Previous studies have indicated that the transcription-
al profile in insulin-resistant muscle might be more di-
rected towards fat storage than oxidation. Although 
Morino et al.  [47] reported similar gene expression levels 
in insulin-resistant and healthy controls, other studies 
have indicated a reduced expression of PGC1  and oxi-
dative genes as early factors in the etiology of T2DM  [14, 
23, 24, 48] . Moreover, an upregulation of ACC-2 has been 
observed in T2DM patients compared with lean subjects 
 [14] . This could not be confirmed in the present study, 
which did not show a decreased expression of PGC1  or 
an increased expression of ACC-2 in IGT men compared 
to NGT men in the fasted state. Although we cannot ex-
clude that we missed small differences between groups 
(effect size  ! 1.82 as normalized expression), this does not 
explain most discrepancies between our data and the re-
sults of several previous studies. Differences in the degree 
of insulin resistance between the subject groups of the 
individual studies may have played a role. In most stud-
ies, more extreme phenotypes are compared. In our 
study, the differences in insulin resistance were less ex-
treme and the subjects were comparable in  terms of obe-
sity, which may explain the absence of relevant numerical 
differences in baseline gene expression that were ob-
served.
 The second objective of the present study was to define 
whether weight loss could have an impact on the expres-
sion of genes involved in FA handling. Weight loss sig-
nificantly increased insulin sensitivity (by 71%) and tend-
ed to improve muscle oxidative capacity as evidenced by 
CS activity. Nevertheless, our data do not support an im-
provement on the transcriptional level of the genes exam-
ined here. This is consistent with Simoneau et al.  [11] who 
also did not detect changes in several different markers 
of skeletal muscle FA metabolism in obese NGT men af-
ter a weight loss intervention based on a very low-calorie 
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diet, but is not consistent with all other studies showing 
an upregulation of genes involved in lipid oxidation  [28, 
29, 49] . This may be explained by the finding that no ap-
parent disturbances at the basal transcriptional level were 
present between NGT and IGT men and that, possibly, 
the expression of these genes is not regulated by obesity 
per se. Small differences after weight loss may have been 
missed because of the relatively small sample size, and the 
results will need confirmation from other studies.
 In conclusion, insulin could acutely increase the ex-
pression of PGC1  , SREBP-1c, SREBP-2, and ACC-2 in 
obese subjects. Accumulating data indicate that defects 
in insulin-regulated gene expression may be involved in 
the etiology of insulin resistance and T2DM. In the pres-
ent study, SREBP-2 was identified as a potential novel 
candidate because of its altered insulin responsiveness in 
IGT men compared with NGT men.
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